La vendita allo scoperto per Henry Schein dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Henry Schein. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Henry Schein (NASDAQ:HSIC) Azioni, Report sulle vendite allo scoperto

Henry Schein

Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services to office-based dental and medical practitioners, as well as alternate sites of care. The company's reportable segments are global Distribution and Value-Added Services; global Specialty Products; and global Technology. It generates the majority of its revenue from the global Distribution and Value-Added Services segment which includes distribution to the global dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services.

Henry Schein Inc

News

Management

HSIC

James P. Breslawski To Step Down As President Of Henry Schein

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>UBS cut Henry Schein, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) price target from $83 to $80. UBS analyst Kevin Caliendo maintained a Neutral rating. Henry Schein shares closed at $75.82 on Tuesday. See how other <a href="https://www.benzinga.com/quote/CRWD/analyst-ratings">analysts view this stock</a>.</li>
<li>Piper Sandler raised the price target for Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) from $94 to $110. Piper Sandler analyst Yasmeen Rahimi maintained an Overweight rating. Prothena shares closed at $14.63 on Tuesday. <a href="https://www.benzinga.com/quote/PRTA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity increased ZoomInfo Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) price target from $14 to $15. Canaccord Genuity analyst David Hynes maintained a Buy rating. ZoomInfo shares closed at $9.53 on Tuesday. <a href="https://www.benzinga.com/quote/CRWD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs cut the price target for ZipRecruiter, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIP#NYSE">ZIP</a>) from $9 to $8. Goldman Sachs analyst Eric Sheridan maintained a Neutral rating. ZipRecruiter shares closed at $6.73 on Tuesday. <a href="https://www.benzinga.com/quote/ZIP/analyst-ratings">See how other analysts view this stock.</a></li>
<li>RBC Capital raised the price target for agilon health, inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) from $3 to $3.5. RBC Capital analyst Sean Dodge maintained an Outperform rating. agilon health shares closed at $3.63 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/AGL/analyst-ratings">view this stock</a>.</li>
<li>Roth MKM cut Shoals Technologies Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) price target from $5 to $4.5. Roth MKM analyst Philip Shen maintained a Neutral rating. Shoals Technologies Sports shares settled at $4.2650 on Tuesday. <a href="https://www.benzinga.com/quote/SHLS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer slashed Maplebear Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) price target from $65 to $60. Oppenheimer analyst Jason Helfstein maintained an Outperform rating. Maplebear Brands shares closed at $48.78 on Tuesday. <a href="https://www.benzinga.com/quote/CART/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho raised Check Point Software Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>) price target from $220 to $230. Mizuho analyst Gregg Moskowitz maintained a Neutral rating. Check Point Software shares closed at $218.63 on Tuesday.  <a href="https://www.benzinga.com/quote/CHKP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan increased the price target for Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) from $200 to $209. JP Morgan analyst Jessica Fye maintained an Overweight rating. Jazz Pharmaceuticals shares settled at $139.67 on Tuesday. <a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS increased CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) price target from $396 to $450. UBS analyst Roger Boyd maintained a Buy rating. CrowdStrike shares closed at $379.75 on Tuesday. <a href="https://www.benzinga.com/quote/CRWD/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43981181/nvidia-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Nvidia Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Price Target

Markets

Analyst Ratings

Trading Ideas

CART

CHKP

CRWD

JAZZ

PRTA

SHLS

CrowdStrike To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Wednesday

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Henry Schein, presenting an average target of $82.71, a high estimate of $90.00, and a low estimate of $75.00. This upward trend is evident, with the current average reflecting a 3.13% increase from the previous average price target of $80.20.
<img src="https://www.benzinga.com/files/images/story/2025/1740596427_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Henry Schein's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$80.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$80.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$80.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$84.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Neutral</td>
<td>$75.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Henry Schein. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Henry Schein compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Henry Schein's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HSIC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Henry Schein analyst ratings.</a>
<h2>Unveiling the Story Behind Henry Schein</h2>
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services primarily to office-based dental and medical practitioners, as well as alternate sites of care. The company operates in two reportable segments; health care distribution and technology &amp; value-added services. The healthcare distribution segment is engaged in combining global dental and medical businesses and distributes consumable products, small equipment, laboratory products, and Vitamins. The technology and value-added services reportable segment provides software, technology &amp; other value-added services to health care practitioners. The majority of revenue is derived from the health care distribution segment.
<h3>Henry Schein: A Financial Overview</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Positive Revenue Trend: Examining Henry Schein's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 0.38% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Henry Schein's net margin excels beyond industry benchmarks, reaching 3.12%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Henry Schein's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.82%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Henry Schein's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.95% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.85, Henry Schein adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Henry Schein: 7 Analysts Share Their Views

UBS analyst Kevin Caliendo maintains Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) with a Neutral and lowers the price target from $83 to $80.

UBS Maintains Neutral on Henry Schein, Lowers Price Target to $80

Barrington Research analyst Michael Petusky maintains Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) with a Outperform and maintains $90 price target.

Barrington Research Maintains Outperform on Henry Schein, Maintains $90 Price Target

On Tuesday,&nbsp;Henry Schein Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NYSE">HSIC</a>) reported a fourth-quarter adjusted EPS of $1.19, up 80.3% year-over-year,&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">missing the consensus of $1.21</a>.
Sales were $3.19 billion, an increase of 5.8%, missing&nbsp;the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43934994/henry-schein-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-detailed-202" rel="noreferrer noopener">consensus of $3.30 billion</a>.
Sales growth reflects 5.5% internal sales growth, 0.7% sales growth from acquisitions, and a 0.4% sales decrease resulting from foreign currency exchange. Excluding the impact of personal protective equipment (PPE) and COVID test kits, internal sales growth was 6.6%.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42470172/what-does-dental-player-pattersons-41-billion-deal-mean-for-other-players-analyst-outlines" rel="noreferrer noopener">What Does Dental Player Patterson&#8217;s $4.1 Billion Deal Mean For Other Players?</a>
"Our fourth quarter financial results reflect relatively stable dental and medical end-markets. We continued to make progress on our 2022 to 2024 BOLD+1 Strategic Plan which we recently completed, exceeding our 2024 target of generating 40% of our worldwide operating income from high-growth, high-margin businesses," said Stanley Bergman, chairman and CEO of Henry Schein.
As part of the new strategy, the company has restructured its organization into three segments:
<ul>
<li>Global Distribution and Value-Added Services ($10.8 billion in sales)</li>
<li>Global Specialty Products ($1.4 billion in sales)</li>
<li>Global Technology ($630 million in sales)</li>
</ul>
According to William Blair, it is &#8220;difficult to get an initial read on which segments underperformed.&#8221;
The firm&#8217;s analysts assume continued weakness in dental end-markets weighed on the dental segment, &#8220;especially for equipment and to some degree maybe even merchandise.&#8221;
Guidance: Henry Schein forecasts 2025 adjusted EPS of $4.80-$4.94 versus a consensus of $5.01. The company also expects sales growth of approximately 2%-4% over 2024.
Analyst Brandon Vazquez notes that the company&#8217;s 2025 outlook is slightly below Wall Street expectations, likely due to stable but weak market demand and spending on future growth, such as a new e-commerce site, which could temporarily impact profit margins.
Price Action:&nbsp;At last check on Tuesday, HSIC stock was down 3.91% at $74.61.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/buybacks/25/02/43940680/trip-com-shares-drop-despite-strong-q4-earnings-and-record-travel-demand-details" target="_blank" rel="noreferrer noopener">Trip.com Shares Drop Despite Strong Q4 Earnings and Record Travel Demand: Details</a></li>
</ul>
Image: Shutterstock

Analyst Color

Earnings

Large Cap

Guidance

Health Care

Movers

General

Henry Schein Q4 Earnings And Outlook Miss Expectations, Restructures For Growth

2025 Financial Guidance
Henry Schein today provided financial guidance for 2025. Guidance is for current continuing operations as well as announced acquisitions and does not include the impact of restructuring and integration expenses, amortization expense of acquired intangible assets, any potential insurance claim recovery associated with the cybersecurity incident and costs associated with shareholder advisory matters. This guidance also assumes that foreign currency exchange rates remain generally consistent with 2024 levels and modest improvement in the dental and medical markets during the year.
<ul>
<li>2025 non-GAAP diluted EPS attributable to Henry Schein, Inc. is expected to be $4.80 to $4.94, reflecting growth of 1% to 4% compared with 2024 non-GAAP diluted EPS of $4.74.</li>
<li>2025 total sales growth is expected to be approximately 2% to 4% over 2024.</li>
<li>2025 Adjusted EBITDA3 growth is expected to increase mid-single digits compared with 2024.</li>
</ul>

Henry Schein Forecasts 2025 Adjusted EPS Of $4.80-$4.94 Versus Consensus Of $5.01, With Sales Growth Of Approximately 2%-4% Over 2024

Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) reported quarterly earnings of $1.19 per share which missed the analyst consensus estimate of $1.21 by 1.65 percent. This is a 80.3 percent increase over earnings of $0.66 per share from the same period last year. The company reported quarterly sales of $3.18 billion which missed the analyst consensus estimate of $3.30 billion by 3.53 percent. This is a 5.37 percent increase over sales of $3.02 billion the same period last year.

Henry Schein Q4 2024 Adj EPS $1.19 Misses $1.21 Estimate, Sales $3.18B Miss $3.30B Estimate

AHCO

ALLT

ARQT

AXGN

AXON

BASE

BGFV

BLZE

BTDR

BWIN

CAVA

CBLL

CCCS

CECO

CGBD

CHRD

CIFR

CPNG

CPSS

DAWN

DNUT

DOCN

DRVN

ELAN

EXLS

FIHL

FLYW

FSLR

FULC

GPOR

HRMY

HURN

HYLN

IART

ICCC

IGIC

IMOS

INGN

INTU

INVX

IPAR

ITRI

IVAC

JACK

KEYS

KNSA

LCID

LGIH

LIVN

LMND

LXFR

MASI

MATX

MFIC

MIDD

MMSI

MPLN

MRVI

NOVT

NXRT

Earnings Scheduled For February 25, 2025

Henry Schein's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NYSE">HSIC</a>) short percent of float has fallen 16.17% since its last report. The company recently reported that it has 5.77 million shares sold short, which is 5.34% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.37 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Henry Schein Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740158115_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Henry Schein has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Henry Schein's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Henry Schein's peer group average for short interest as a percentage of float is 4.25%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Is Henry Schein Gaining or Losing Market Support?

Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Wells Fargo analyst Vik Chopra initiated coverage on Henry Schein, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) with an Equal-Weight rating and announced a price target of $80. Henry Schein shares closed at $77.62 on Thursday. <a href="https://www.benzinga.com/quote/HSIC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Maxim Group analyst Michael Okunewitch initiated coverage on Mainz Biomed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) with a Buy rating and announced a price target of $14. Mainz Biomed shares closed at $6.53 on Thursday. <a href="https://www.benzinga.com/quote/MYNZ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Benchmark analyst David Williams initiated coverage on Analog Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) with a Buy rating and announced a price target of $245. Analog Devices shares closed at $209.34 on Thursday. <a href="https://www.benzinga.com/quote/ADI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Vik Chopra initiated coverage on Align Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) with an Overweight rating and announced a price target of $255. Align Tech shares closed at $204.89 on Thursday. <a href="https://www.benzinga.com/quote/ALGN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Lake Street analyst Jaeson Schmidt initiated coverage on BK Technologies Corporation (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BKTI#AMEX">BKTI</a>) with a Buy rating and announced a price target of $40. BK Technologies shares closed at $28.97 on Thursday. <a href="https://www.benzinga.com/quote/BKTI/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ADI stock? Here&#8217;s what analysts think:
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/14084410/image-2-43-1024x585.png" alt="" class="wp-image-783129" style="width:580px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/14084410/image-2-43-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/14084410/image-2-43-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/14084410/image-2-43-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/14084410/image-2-43.png 1138w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43692962/top-3-consumer-stocks-you-may-want-to-dump-in-february">Top 3 Consumer Stocks You May Want To Dump In February</a></li>
</ul>

Initiation

Pre-Market Outlook

ALGN

BKTI

CRSP

MYNZ

XRAY

This Analog Devices Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Wells Fargo analyst Vik Chopra initiates coverage on Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) with a Equal-Weight rating and announces Price Target of $80.

Wells Fargo Initiates Coverage On Henry Schein with Equal-Weight Rating, Announces Price Target of $80

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) in the last three months.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $82.2, with a high estimate of $90.00 and a low estimate of $75.00. Observing a 6.06% increase, the current average has risen from the previous average price target of $77.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1738260043_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of Henry Schein by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$80.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$84.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Neutral</td>
<td>$75.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$82.00</td>
<td>$82.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Henry Schein. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Henry Schein compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Henry Schein's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Henry Schein's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HSIC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Henry Schein analyst ratings.</a>
<h2>Get to Know Henry Schein Better</h2>
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services primarily to office-based dental and medical practitioners, as well as alternate sites of care. The company operates in two reportable segments; health care distribution and technology &amp; value-added services. The healthcare distribution segment is engaged in combining global dental and medical businesses and distributes consumable products, small equipment, laboratory products, and Vitamins. The technology and value-added services reportable segment provides software, technology &amp; other value-added services to health care practitioners. The majority of revenue is derived from the health care distribution segment.
<h3>Henry Schein: Delving into Financials</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Henry Schein displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 0.38%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Henry Schein's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 3.12%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Henry Schein's ROE excels beyond industry benchmarks, reaching 2.82%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Henry Schein's ROA stands out, surpassing industry averages. With an impressive ROA of 0.95%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.85, Henry Schein adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Henry Schein Stock

Barrington Research analyst Michael Petusky maintains Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) with a Outperform and raises the price target from $82 to $90.

Barrington Research Maintains Outperform on Henry Schein, Raises Price Target to $90

Henry Schein, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) shares are trading higher on Wednesday. The medical and dental supplies distributor disclosed a strategic investment of an additional $250 million from funds affiliated with KKR &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>).
With this investment, KKR will become the largest non-index fund shareholder, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b43298127/henry-schein-announces-strategic-investment-by-kkr-board-changes-and-provides-preliminary-unaudite" rel="noreferrer noopener">holding a 12% stake in the company.</a>
The company will also have the option to increase its equity stake up to 14.9% through open market purchases. Henry Schein and KKR will collaborate on a range of value-creation opportunities.
Henry Schein will issue new shares of common stock to funds affiliated with KKR for a $250 million investment based on the market price.
KKR is primarily funding this investment through North America Fund XIII. The completion of the transactions is subject to standard closing conditions.
As part of the arrangement between Henry Schein and KKR, Max Lin and William Daniel will join Henry Schein's Board of Directors as independent directors. Additionally, the Board has appointed Robert Hombach as an independent director.
In addition, Henry Schein&#8217;s Board has authorized an increase of $500 million to its share repurchase program, with $250 million to be executed through accelerated share repurchases.
Preliminary Results: Henry Schein sees fourth-quarter preliminary revenue of $3.2 billion (vs. consensus of $3.35 billion), bringing the 2024 revenue to $12.7 billion <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">(vs. street view of $12.8 billion)</a>.&nbsp;&nbsp;
The company sees fourth-quarter preliminary adjusted EPS of $1.19 (vs. consensus of $1.23) and 2024 adjusted EPS of $4.74 (vs. consensus of $4.78).
2025 Outlook: Henry Schein expects both revenues and adjusted EPS to grow in the range of low to mid-single digits in 2025.
The company projects adjusted EBITDA to grow in a <a href="https://www.benzinga.com/calendars/guidance">mid-single-digit range in 2025.</a>
The company plans to release its fourth quarter and full-year 2024 financial results <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">on Tuesday, February 25, 2025</a>.
Investors can gain exposure to HSIC via AdvisorShares Focused Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWS#NYSE">CWS</a>) and Invesco Bloomberg Analyst Rating Improvers ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPGD#NYSE">UPGD</a>).
Price Action: HSIC shares are up 6.48% at $81.03 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42855275/bofa-securities-upgrades-healthcare-giants-cardinal-health-henry-schein" target="_blank" rel="noreferrer noopener">Headline Risks Affecting Healthcare Tech &amp; Distribution Sector Will Likely Continue in 2025: BofA Analyst</a></li>
</ul>
Photo via Shutterstock.

Equities

UPGD

KKR Sinks Its Teeth Into Henry Schein With Additional Investment And Board Seats: Details

Henry Schein Sees Prelim. Q4 Non-GAAP EPS $1.19 vs $1.23 Est.

Buybacks

Henry Schein Increases Buyback By $500M

Hedge Funds

Henry Schein Announces KKR Will Become 12% Shareholder, Will Add Two Reps To Board

WIIM

Henry Schein shares are trading higher following a Wall Street Journal report indicating KKR has taken a stake in the company and will receive two board seats.

<a href="https://www.wsj.com/business/deals/kkr-builds-stake-in-medical-supply-company-reaches-deal-for-board-seats-ed915f3c?mod=Searchresults_pos1&amp;page=1" title="https://www.wsj.com/business/deals/kkr-builds-stake-in-medical-supply-company-reaches-deal-for-board-seats-ed915f3c?mod=Searchresults_pos1&amp;page=1">https://www.wsj.com/business/deals/kkr-builds-stake-in-medical-supply-company-reaches-deal-for-board-seats-ed915f3c?mod=Searchresults_pos1&amp;page=1</a>

Insider Trades

The Wall Street Journal Reported KKR Has Taken A Big Stake In Henry Schein, Will Get Two Board Seats

Press Releases

Henry Schein Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Detailed 2025 Financial Guidance

Nominations Now Open for Henry Schein Medical's Athletics and Schools 2025 Rising Star Award

Henry Schein to Participate in Upcoming Investor Conference in March

Ethisphere Names Henry Schein as One of the 2025 World's Most Ethical Companies® for 14th Consecutive Year

Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

Henry Schein Donates Health Care Products to Support Special Olympics Healthy Athletes® Screenings at Special Olympics World Winter Games 2025 in Turin, Italy

Henry Schein Will Showcase a Selection of the Company's Comprehensive Solutions for Oral Health Professionals at the 2025 International Dental Show

Henry Schein Received Validation of Net-Zero Science-Based Targets

Henry Schein to Webcast First Quarter 2025 Conference Call on Monday, May 5th, 2025, at 8:00 a.m. ET

Comments

Henry Schein

Vendite allo scoperto

Henry Schein (NASDAQ:HSIC) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO